with Prof. Dr. Dr. h.c. Werner Weidenfeld. Werner Weidenfeld is a member of the Board of Directors of the Bertelsmann Foundation and publisher of the magazine "Internationale Politik". Among his other assignments in international research and political bodies he is the Chairman and Scientific Director of the Institute for European Policy in Berlin, on the Advisory Board
for European studies at the Chicago Council on Foreign Relations, Chicago, as well as an associate member of the Club of Rome.

SHL Telemedicine reports on further progress in its German operations. Financial results for Q3 in line with expectations - USD 4.6 million net profit due to capital gain.

and divesture of Bikurofe in Israel which will result in around USD 9 million capital gain in Q3. Financial results for the period in line with expectations.

for the divesture of Bikurofe Ltd. As previously announced, SHL also received from Bikurofe payment of previously announced dividends and other debts in the amount of USD 4.3 million and will continue to render various services to Bikurofe for a total amount of USD 1.5 million.

its Israeli outpatient clinics and doctor visit services. SHL expects to record a capital gain of around USD 9 million.
The divesture of Bikurofe is in line with SHL's stated strategy to focus on its core telemedicine activities. Based on the recent progress of its international telemedicine operations, SHL is concentrating on the growth opportunities in Germany and the U.S.

for the procurement of telemedicine solutions to the insurer's heart patients.
Deutsche BKK is to purchase for its members with chronic heart diseases, including congestive heart failure (CHF), the SHL telemedicine monitoring solution.

marked by significant contracts in Germany and US.
Financial performance in line with its expectations.
In Germany,Taunus Betriebskrankenkasse, a Frankfurt based health insurance company, has entered into an agreement for the utilization of the SHL telemedicine solution for their members with chronic heart diseases while in the US SHL entered into an exclusive marketing alliance with St. Jude Medical (the world's leading mechanical heart valve company) for the promotion of the INR@Home anticoagulation blood monitoring system.

in its overseas markets in Germany and in the U.S. in 2004.
This is the first time that SHL's revenues have surpassed the USD 100 million mark. In 2004, revenues were USD 103.1 million, an increase of 4.3% compared to 2003 reflecting the continuing growth of the Company's activities.

procures SHL’s TM solutions for their members with chronic heart diseases
This cooperation is expected to add substantially to PHTS's growth and marks an important milestone. SHL estimates that revenues from this agreement will amount to a number of millions of dollars, already in 2005. Furthermore, it underpins PHTS's position as the leading
German Telemedicine provider and the potential for its solutions in Germany.

with St. Jude Medical GmbH for ICD monitoring Serious rhythm dysfunctions can cause sudden death which can be prevented by
implanted cardioverter-defibrillators. The ICD is smaller than a matchbox and when recognizing rhythm disorders delivers an electric shock, bringing the heart beat back to the right rhythm. Patients with ICD's need to check the device every three months.